Elahere (mirvetuximab soravtansina-gynx)

Elahere (mirvetuximab soravtansine-gynx) is a medication that combines an antibody and a drug, called ADC, with a microtubule inhibitor, is used to treat epithelial ovarian, fallopian tube, or peritoneal cancer that is positive for a specific protein called FR-alpha and resistant to platinum. It was approved by the FDA in November 2022.